Monster Beverage Corp (MNST) Stock Price Today
Aura AI Summary
Key Stats
- $95.25BMarket Cap
- -Volume
- Consumer StaplesSector
- $97.6452W High
- $58.6552W Low
- -Typical Hold Time
- $93.54BEnterprise Value
- -Div Yield
- -Trading Activity
Track Monster Beverage Corp (MNST) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Monster Beverage Corp has traded between a low of $58.65 and a high of $97.64, highlighting its annual price range. Buy and sell Monster Beverage Corp shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Most Recent News
Aberdeen Municipal Income Fund offers monthly tax-exempt income with active management and increased distributions.
Aberdeen Municipal Income Fund provides investors a chance to earn monthly, tax-exempt income by leveraging an active, research-driven strategy that includes macroeconomic insight, credit analysis, and high-yield municipal bonds. The fund recently in...
Uber expands beyond rides and delivery into travel, financial services, and autonomous vehicle data.
Uber is broadening its services beyond ride-hailing and food delivery to include hotel bookings, boat rentals, and shopping features, aiming to become a travel-focused platform. It is also developing financial products for drivers and merchants, such...
Mesoblast completes treatment of 300 patients in Phase 3 trial for chronic low back pain therapy.
Mesoblast has reached its goal of treating 300 patients in its pivotal Phase 3 trial of rexlemestrocel-L, a cell therapy for chronic low back pain caused by degenerative disc disease. This trial aims to confirm pain reduction benefits seen in earlier...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.